Editas Medicine
EDIT
68 hedge funds and large institutions have $550M invested in Editas Medicine in 2016 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 21 increasing their positions, 10 reducing their positions, and 8 closing their positions.
238% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 8
110% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 10
39% more funds holding
Funds holding: 49 → 68 (+19)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
12% less capital invested
Capital invested by funds: $623M → $550M (-$73.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$5.25M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.22M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$1.96M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.69M |
| 5 |
Renaissance Technologies
New York
|
+$752K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$14.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.33M |
| 3 |
WCM
Wildcat Capital Management
New York
|
-$6.34M |
| 4 |
CC
Casdin Capital
New York
|
-$2.95M |
| 5 |
JP Morgan Chase
New York
|
-$2.5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
First Manhattan
New York
| – | -$17K | -500 | Closed |
|
EDIT Hedge Fund Activity: Q2 2016 in Review
68 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q2 2016, worth a combined $550M — down 12% from $623M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new EDIT positions and 8 closed out — a net gain of 19 holders — while 21 added to existing stakes and 10 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $5.25M. The largest seller was Viking Global Investors, cutting an estimated $14.4M.
- 68 institutional investors held Editas Medicine (EDIT) as of Q2 2016, up from 49 in Q1 2016.
- Funds reported $550M of Editas Medicine stock for Q2 2016, down 12% quarter-over-quarter.
- 27 funds opened new Editas Medicine positions in Q2 2016 and 8 closed out, a net change of +19 holders.
- The largest Editas Medicine buyer in Q2 2016 was Morgan Stanley, an estimated $5.25M added.
- The largest Editas Medicine seller in Q2 2016 was Viking Global Investors, an estimated $14.4M sold.
Based on aggregated 13F filings for Q2 2016.